彩盈彩票

NEWS more +

  • Zai Lab Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Updates

  • Zai Lab Announces Acceptance of sNDA Submission of ZEJULA (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA

  • Zai Lab Announces Acceptance of NDA Submission of Omadacycline in China by the NMPA

友情链接:欢乐pk10  彩盈彩票  三国彩票平台  半岛娱乐彩票平台  北京28  乐宝彩票平台  幸运飞艇网站平台  豪享彩票官网  幸福彩票平台  快乐8网址登陆